Introduction
The treatment of giant cell tumour remains controversial, with various forms of therapy being employed including curettage and bone grafting, local excision, resection arthrodesis, radiotherapy alone or in combination with other methods, and endoprosthetic replacement.
Conservative surgery by curettage and bone grafting is the most widely used form of primary treatment. However, this is followed by a recurrence rate varying from 34% to 50% at various anatomical sites'-3. Thomson and Turner-Warwick4 reported a 90% recurrence after this form of treatment. In addition to this high rate of recurrence, approximately 10% of giant cell tumours of bone become frankly malignant, particularly if they receive radiation along with other forms of therapy and occasionally produce metastases even though histologically benign5.
Endoprosthetic replacement in suitable sites is usually employed as a secondary procedurefor recurrences and subsequent complications such as pathological fractures.
Giant cell tumours represent approximately 3% to 4% of all malignant bone tumours including myeloma"3. As the proximal femur is an uncommon site for this rare primary bone tumour, there is little information in the literature about the results of a particular form of treatment at this anatomical site. To evaluate the effectiveness of primary treatment by curettage and bone grafting, 4 cases of giant cell tumour of the femoral head and neck treated at the Nuffield Orthopaedic Centre have been reviewed.
Case reports
Between 1970 and 1982, 14 cases of giant cell tumour were treated at the Nuffield Orthopaedic Centre. The upper tibia was involved in 4 cases, lower femur in 3, humerus in 2, ulna in one, and the femoral head and neck in 4. These last 4 cases are reported here. Case 1: A 19-year-old married woman presented with a six-week history of pain in the right groin. Apart from slight irritability of the hip joint, there were no positive findings on clinical examination. X-rays of the right hip revealed a lytic lesion in the femoral head and neck which was eccentrically placed ( Figure 1A ). There was no evidence in periosteal new bone formation and the advancing margins of the lesion were lacking in reactive bony sclerosis. Biopsy of the lesion confirmed a giant cell tumour. This was treated by thorough curettage and iliac cortico-cancellous bone grafting. X-ray three months postoperatively confirmed satisfactory incorporation ofthe graft ( Figure 1B) .
One year postoperatively the patient complained of some discomfort in the right hip. X-rays of the hip approach with trochanteric osteotomy. The head and neck of the femur were excised well below the level of the lesion. A frozen section of biopsy confirmed the total clearance of the tumour.
Nine years later there is no evidence of a recurrence and her hip arthroplasty ( Figure 1D ) continues to function well. Case 2: A 22-year-old man treated for a giant cell tumour of the right femoral head and neck ( Figure  2A ) had the lesion thoroughly curetted and the cavity filled with bone chips and keil bone ( Figure  2B ). Six years later he presented at the Nuffield Orthopaedic Centre with a two-year history of intermittent pain in the right hip. X-rays confirmed a recurrence of the lesion, which had extended down to the inter-trochanteric line ( Figure 2D ). Review of earlier X-rays showed that radiological evidence of a recurrence was already present two years after the primary treatment (Figure 2c ).
He underwent a Chamley total hip replacement through a lateral approach with trochanteric osteotomy ( Figure 2E ). The femoral head and neck were excised and a frozen section biopsy confirmed that the line of femoral section was well clear of the tumour. Three years later he has satisfactory hip function with no sign of recurrence.
Case 3: A 33-year-old Portuguese woman was initially treated locally for 'benign giant cell tumour' of the right femoral head and neck ( Figure 3A ) by curettage and bone grafting. Six months later pair in the hip recurred and she underwent a further curettage and bone grafting together with a McLoughlin nail plate fixation of the neck of femur. Eighteen months later X-rays revealed an osteolytic defect in the femoral neck ( Figure 3B ) and at this stage the patient was referred for further investigation and treatment. The only symptom at this time was an ache in the hip. Further X-rays, tomograms and bone scan (Figure 3c ) all suggested a recurrence.
At operation a lateral approach to the hip was employed. The pin and plate were removed, and the femoral head and neck containing the tumour were excised. A frozen section biopsy confirmed the diagnosis of a recurrent giant cell tumour and that the line of the femoral section was well clear of the tumour.
A Charnley total hip replacement was performed ( Figure 3D ) and three years later the patient has near normal hip function and no evidence of recurrence.
Case 4: A 16-year-old
Greek girl was initially treated in Istanbul for a giant cell tumour of the femoral head and neck by curettage and bone grafting ( Figure 4A,B ). One and a half years later the lesion recurred ( Figure 4c ) and at this stage she presented at the Nuffield Orthopaedic Centre for further treatment.
At operation a lateral approach with trochanteric osteotomy was employed, and the tumour excised. A frozen section' biopsy confirmed the diagnosis of a recurrent giant cell tumour. Curette biopsies (frozen section) from three points on the cut surface of the distal femur excluded any evidence of tumour in the biopsy specimens. A Charnley total hip arthroplasty was performed ( Figure 4D ) and follow up at four years has demonstrated satisfactory hip function and no evidence of recurrence.
Discussion
Most recurrences of giant cell tumour develop within two years of primary treatment2'5'6 and our patients were no exception. The unpredictable clinical behaviour of giant cell tumours and the need for prolonged, regular and careful follow up have also been emphasized by many authors5'7. The histological grading suggested by Jaffe and colleagues8 indicates the aggressiveness of giant cell tumours, but it does not reliably predict the potential for local recurrence or pulmonary metastases, particularly in cases of Grade 1 and 2 lesions2'3'8'9.
The practical difficulty of total clearance of giant cell tumour by curettage in the femoral neck has been observed by other authors4'8"l0 12* The use of cryotherapy to necrotize the wall of the cavity after curettage has been advocated to reduce the recurrence rate'3"l4, but the value of this measure is con-troversial'5"6. Dahlin"7 found that cautery after curettage or excision did not influence the recurrence rate. Irradiation of the giant cell tumour is unjustified unless a lesion is surgically inaccessible, as it is associated with a high rate of recurrence and delayed complications such as osteonecrosis and sarcomatous changes6.
Dahlin17 reported that amputation or total excision was uniformly curative and that less radical primary treatment gave worse results. This was supported by the work of Goldenberg et al.2. Johnson and Dahlin5 also stated that early excision when the lesion is small involves less loss of bone and easier replacement whether by graft or prosthesis than excision used as a secondary form of treatment. At the hip, total excision of the lesion cannot be effected without injury to the articular surface. Hence reconstruction of the joint becomes a necessity.
The first reported case of a successful prosthetic implant for tumour was for a recurrent giant cell tumour of the proximal femur"8. Further work by Burrows and co-workers"9 has advanced the surgical approach to tumour resection and restoration of the defects by custom-built prostheses.
Endoprosthetic replacement of the proximal femur has been reported to give good functional and pain-free results20. In a biomechanical evaluation of proximal femur and custom hip joint replacement following segmental resection of bone tumours, Sim and Chao2" reported a virtually normal pattern of gait and function of the hip muscles. Dobbs et al. 22 , in a study of 81 patients with 88 replacements of the hip and proximal femur for bone tumours, reported the probable 10-year survival for osteoclastoma as 90%. These results suggest that prosthetic replacement offers an effective form of treatment with unimpaired longevity, improved quality of life, and reduced morbidity. Recurrences following curettage and bone grafting, on the other hand, may well compromise the result.
In view of the 100% recurrence following curettage and grafting at this anatomical site, and the possibility of malignant transformation by repeated surgical intervention17, it is concluded that a radical approach to the treatment of giant cell tumour of the femoral head and neck is justified.
Although there may be reluctance to advise hip replacement arthroplasty as the primary treatment of choice in young patients, the likelihood of recurrence following curettage and bone grafting, particularly at this anatomical site, must be stressed. It may be that hip replacement arthroplasty should be considered the primary treatment of choice rather than reserving it as a secondary procedure for recurrences and associated complications.
